Our Leadership
BC3 Technologies:
A Legacy of Expertise and Innovation
At BC3 Technologies, our core team embodies a rich legacy of professional expertise and industry knowledge. Collectively, we bring a remarkable 76 years of experience in the manufacturing sector, demonstrating a deep understanding of the intricacies and challenges of production processes and supply chain management. This extensive background ensures that our operations are efficient, innovative, and aligned with the highest industry standards.
Our team's proficiency extends significantly into the realm of organic chemistry, with a combined experience of 42 years. This expertise underpins our ability to innovate and develop cutting-edge solutions, particularly in the formulation of our medical products. It's this deep-seated knowledge in chemistry that allows us to create products that are not only effective but also safe and reliable.
In the specialized field of medical device and drug manufacturing, our team boasts 35 years of experience. This experience is crucial in navigating the complex landscape of medical product development, from initial concept to market release. Our team's expertise ensures that each product we develop meets rigorous medical standards and fulfills the needs of healthcare professionals and patients alike.
Furthermore, our corporate accounting and financial management expertise, spanning 30 years, forms the backbone of our operational integrity and fiscal responsibility. This experience is vital in guiding the company through strategic financial planning, ensuring sustainable growth, and maintaining transparency and compliance in all our financial dealings.
At BC3 Technologies, we believe that our team's diverse and extensive experience is our greatest asset. It's this blend of skills and knowledge that positions us at the forefront of innovation in our field, driving our mission to develop products that make a real difference in the lives of those we serve.
CEO and Co-Founder
Wayne Grube, Jr.
Mr. Grube serves as CEO and founder of BC3 Technologies. As Vice President of Baltimore-based Aerosol and Liquid Packaging, Mr. Grube has robust experience in project ideation, development, and execution with specific background in chemistry and federal regulation. Mr. Grube has deep knowledge of commercialization from his experience in manufacturing, large-scale consumer and B2B retail, and finance.
COO
Lee Jay, Jr.
Mr. Jay serves as COO and is President of Baltimore-based Aerosol and Liquid Packaging, an FDA- and EPA-registered company that partners to develop and manufacture medical and industrial products. With 20+ years experience in the aerosol Industry, Mr. Jay possesses a deep understanding of QA, operations and processes for aerosols, liquids, gels, and powders. He has additional experience in compounding formulas, hazardous materials, and R&D.
CFO
Karen Shenk
Ms. Shenk serves as CFO for BC3 Technologies and controller for Aerosol & Liquid Packaging. She is responsible for financial reporting, maintenance of accounting records, preparation for annual audits and cash management.
Head, Regulatory Affairs
Rivelino Montenegro, PhD
Dr. Montenegro previously held leading positions in plastics and metal-processing companies in Brazil. He was also research scientist at Matregen in Toronto, where he was responsible for product development/drug delivery. He was a co-founder and director of Smart Biotech, Toronto, responsible for R&D for medical devices for stroke. In 2006, he founded Medovent together with Dr. Freier and is CTO. Since 2016, he is CEO of Monarch Bioimplants, a Swiss-based medical device company focused on cancer treatment strategies. Dr. Montenegro has published 15 peer-reviewed papers and holds several international patents. He obtained his PhD in chemistry at the Max Planck Institute in Golm, Germany.
Head, R&D
Thomas Freier, PhD
Dr. Freier has previously worked at the Center of Excellence for Biomaterials in Rostock, Germany in polymer chemistry and tissue engineering. He was Director of R&D at Matregen, a Toronto-based start-up focused on drug delivery. In 2006, he co-founded Medovent; a medical device company focused on urology and surgery and was CEO until 2016. In 2017, he joined Dr. Montenegro in the management of Monarch Bioimplants. Dr. Freier has published 20 peer-reviewed papers and contributed to five books and holds several international patents. Dr. Freier earned his PhD in chemistry at the University of Rostock.
